Abstract
We demonstrated that dendritic cell (DC) inhibition by tumor-conditioned media in the presence or absence of bevacizumab correlates with colorectal cancer patient survival. Monitoring the influence of the tumor microenvironment on infiltrating immune cells may offer an avenue for the discovery of biomarkers to guide the use of bevacizumab.
| Original language | English |
|---|---|
| Pages (from-to) | 1445-1447 |
| Number of pages | 3 |
| Journal | OncoImmunology |
| Volume | 1 |
| Issue number | 8 |
| DOIs |
|
| Publication status | Published - 2012 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bevacizumab
- Colorectal cancer
- Dendritic cells
- Tumor microenvironment
Fingerprint
Dive into the research topics of 'Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver